NCT04342039View on ClinicalTrials.gov

Epigenetic Health Benefits of Budesonide

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 7, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Epigenetic Effects of Intranasal SteroidsEnvironmental Exposure
Interventions
DRUG

Budesonide Nasal

budesonide 64 mcg/spray; 2 sprays each nostril once daily on days as indicated in the timeline

OTHER

Placebo

2 sprays each nostril daily on days as indicated in the timeline

Trial Locations (1)

V5Z 1M9

University of British Columbia, Vancouver

All Listed Sponsors
collaborator

Genome British Columbia

INDUSTRY

collaborator

Johnson & Johnson Consumer Inc. (J&JCI)

INDUSTRY

lead

University of British Columbia

OTHER